BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BioCentury | Jun 22, 2019
Product Development

Is tau the new amyloid?

After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease, pharmas are lining up behind tau as the next big target. The question is whether they can pick out...
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

One of China's top healthcare analysts, Richard Yeh, said he is departing Goldman Sachs, where he was in global investment research for Asia Pacific. Several Asia-focused bankers and analysts, including Citigroup's Billy Cho, Bank of...
BioCentury | Nov 30, 2017
Company News

Cerecor acquires TRx for $23M

Neurology play Cerecor Inc. (NASDAQ:CERC) acquired therapeutic company TRx Pharmaceuticals LLC for $23 million, comprising $18.9 million in cash and $4.1 million in stock. Cerecor also acquired TRx's pediatric supplement subsidiary Zylera Pharmaceuticals LLC for...
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell was COO of global biosurgery at Sanofi (Euronext:SAN; NYSE:SNY). Cannabinoid company Therapix Biosciences Ltd. (Tel...
BioCentury | Oct 18, 2017
Company News

Management tracks: Gilead, Ipsen, Depomed

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at...
BioCentury | May 25, 2017
Company News

Merck obtains rights to Teijin's tau candidate

Teijin Pharma Ltd. (Tokyo, Japan) granted Merck & Co. Inc. (NYSE:MRK) exclusive rights to an undisclosed preclinical antibody targeting microtubule-associated protein tau (tau; MAPT; FTDP-17). Merck plans to develop the candidate to treat Alzheimer’s disease....
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BioCentury | Dec 17, 2016
Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc. ’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for...
BioCentury | Sep 5, 2016
Company News

Leap Therapeutics, Macrocure deal

Leap will merge with Macrocure in a deal that will create a publicly listed company with two clinical-stage immuno-oncology candidates. Leap’s DKN-01 , a mAb against dickkopf homolog 1 (DKK1) , is in Phase I/II testing for...
Items per page:
1 - 10 of 111